The FDA has approved Novartis’ Diovan HCT (valsartan/hydrochlorothiazide tablets) and Exforge (amlodipine/valsartan tablets) as first-line therapies for hypertension in patients likely to need ...

The Diovan HCT and Exforge first-line approvals were based on several clinical trials in approximately 2,000 and 3,500 patients, respectively, in which both products demonstrated efficacy and ...

Exforge HCT is not indicated for the initial therapy of hypertension. This approval was based on data from a clinical study in more than 2000 patients with moderate to severe hypertension.

Novartis has received a major boost in the USA after regulators there gave their backing to two of the Swiss major’s combination high blood-pressure drugs which can now be used as first-line ...

The Diovan HCT and Exforge first-line approvals were based on several clinical trials in approximately 2,000 and 3,500 patients respectively, in which both products demonstrated efficacy and ...

Regulators in the USA have approved Novartis’ Exforge HCT, the only single pill to combine the three most prescribed high blood pressure treatments in their classes in the country. The US Food and ...

The reductions in SBP/DBP with Exforge HCT® were 7.6/5.0 mm Hg greater than those with valsartan/HCTZ, 6.2/3.3 mm Hg greater than those with amlodipine/valsartan, and 8.2/5.3 mm Hg greater than ...

With Teva being the first to file, the company will enjoy 180 days of marketing exclusivity. As per IMS data, Exforge HCT tablets recorded annual sales of approximately $158 million in the U.S. as ...